Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
IFN-¦Ã, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections. IFN-¦Ã is an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression.
| Products Name (INN Index) | Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B |
|---|---|
| INN Name | interferon gamma |
| Target | IFNGR1 |
| Format | Recombinant Protein |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IFNG (interferon gamma, IFN gamma) |
| VD LC | IFNG (interferon gamma, IFN gamma) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Vidara Therapeutics Ltd. (Dublin Ireland) / Horizon Therapeutics?plc (Dublin Ireland) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IFNGR1 |
| Package |
